Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Department of Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Clin Rheumatol. 2022 May;41(5):1597-1601. doi: 10.1007/s10067-022-06126-x. Epub 2022 Mar 16.
The Pfizer-BioNTech COVID-19 vaccine has been authorized by the U.S. Food and Drug Administration as it demonstrated 95% effectiveness against the SARS-CoV-2 virus. Although the initial vaccine trials showed a favorable side effect profile, there have been concerns regarding activation of aberrant immune responses, triggering autoimmunity. This is a case report of a 68-year-old woman without history of autoimmune conditions, who presented to our emergency department 7 days after receiving the Pfizer-BioNTech COVID-19 vaccine. Her initial symptoms were suggestive of polymyalgia rheumatica, and she had nearly complete response to steroids. Interestingly, she later met criteria for classified systemic lupus erythematous given the development of inflammatory arthritis, positive ANA, and positive dsDNA. The temporal relationship of her symptoms that started 2 days after vaccine administration could suggest a possible association between the Pfizer-BioNTech COVID-19 and the development of systemic lupus erythematous.
辉瑞-BioNTech COVID-19 疫苗已获得美国食品和药物管理局的批准，因其对 SARS-CoV-2 病毒的有效性达到 95%。尽管最初的疫苗试验显示出良好的副作用特征，但人们仍担心异常免疫反应的激活会引发自身免疫。这是一例 68 岁女性的病例报告，她没有自身免疫性疾病史，在接种辉瑞-BioNTech COVID-19 疫苗后 7 天到我们的急诊部就诊。她最初的症状提示为巨细胞性多肌痛，且对类固醇几乎有完全反应。有趣的是，后来由于炎症性关节炎、ANA 阳性和 dsDNA 阳性，她符合分类系统性红斑狼疮的标准。她的症状在疫苗接种后 2 天开始出现，具有时间相关性，这可能表明辉瑞-BioNTech COVID-19 疫苗与系统性红斑狼疮的发展之间存在关联。
